ZHI now offering all global manufacturers interested in becoming a Licensee, its proprietary technology for quantitative and proven Transdermal delivery of CBD.

LAKE WORTH, FLORIDA, US, August 17, 2022 /EINPresswire.com/ — Transdermal technology offers an easy-to-use method of delivering a consistent, steady dose of an active ingredient. The transdermal delivery methodology provides unparalleled safety and control, allowing product use to be discontinued anytime, making accidental overdosing almost impossible.

Robert C. Galler, President & Chairman of ZHI, stated, “We are thrilled with our new lead product, The ZT Patch™, designed to deliver 21.2mg of CBD from hemp. We have validated performance with Kaycha Labs, an independent testing lab. The results of a bioavailability study determined that volunteers who wore the ZT Patch™ for 24 hours showed almost complete delivery of the targeted dosage directly into the body. All ZT Patches™ maintained effective adhesion throughout the test duration.” Galler continued, “We are very excited about our proprietary technology, and I believe it will make the industry much safer by providing better predictive results for all users. This is a breakthrough for…